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poisoning through naloxone prescription programs. Understanding the economic 
burden of opioid poisoning can help inform these efforts and highlight the need 
for further interventions to attenuate current trends. The main objectives of this 
study were to quantify the economic burden of opioid poisoning, estimate the 
cost per poisoning event, and to quantify costs of opioid poisoning for specific 
prescription opioids in the United States. METHODS: A cost-of-illness approach 
was used. Direct costs related to hospitalization and ED visits and estimates  
for mortality and prevalence were obtained from nationally representative 
databases. Other sources of direct costs were obtained from the literature. 
Indirect costs included absenteeism and premature mortality costs, and  
were measured using the human capital method. One-way and probabilistic 
sensitivity analyses were used to test assumptions. RESULTS: Opioid poisoning 
resulted in an economic burden of approximately $20.4 billion in 2009. Eighty-
nine percent was attributed to productivity losses, of which 98% was  
from premature mortality. Approximately $2.2 billion were attributed to direct 
medical costs. Costs for heroin and prescription opioid poisoning were estimated 
to be $4.6 billion and $15.9 billion, respectively. The cost per poisoning event  
was estimated to be $37,274 for all opioids. The cost per poisoning event for 
heroin and prescription opioids was $33,793 and $38,541, respectively. The three 
prescription opioids with the greatest poisoning costs were hydrocodone, 
oxycodone, and methadone. CONCLUSIONS: Opioid poisoning results in  
a significant economic burden to society. Costs related to mortality account  
for the majority of the costs. Interventions that prevent or reverse opioid 
poisoning can have significant impacts on cost, especially where death is 
prevented.  
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OBJECTIVES: To identify relapse in schizophrenia and the main cost drivers  
of relapse using a claims-based algorithm. METHODS: Multistate Medicaid data 
(1997–2010) were used to identify adults with schizophrenia receiving atypical 
antipsychotics (AAPs). The first schizophrenia diagnosis following AAP initiation 
was defined as the index date. Baseline weekly cost was assessed during the  
12 months before the index date, and weekly costs were calculated for ≥2 years 
post index. An algorithm was developed to identify relapse episodes based on 
weeks associated with high cost increase from baseline and high absolute 
weekly cost. Resource use and costs of relapsers during baseline and relapse 
episodes were compared using incidence rate ratios (IRRs) and bootstrap 
methods. No adjustment was made for multiplicity. RESULTS: 9,793 relapsers 
were identified, with a mean of 9 relapse episodes per patient. Duration of 
relapse episodes decreased over time, with a mean(median) duration of 34(4) 
weeks for the first and 8(1) weeks for remaining episodes. Compared with 
baseline, resource utilization during relapse episodes was significantly greater in 
pharmacy, outpatient, and institutional visits (hospitalizations and emergency 
room visits), with IRRs ranging from 1.9–2.4 (all p<.0001). Correspondingly, 
relapse was associated with a mean (95% CI) cost increase of $2459($2384–
$2539)—nearly 6 times larger than mean (median) weekly baseline maintenance 
cost of $425($148). Institutional visits characterized most (53%) of the relapse 
episode incremental costs, with hospitalizations (excluding mental institute 
inpatient admissions) representing 36%. CONCLUSIONS: Relapses in 
schizophrenia patients were associated with cost on average 6 times higher than 
the median maintenance costs. Institutional visits characterized most of the cost 
increase.  
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OBJECTIVES: This study aimed to assess the clinical and economic burden of 
schizophrenia in the U.S. veteran population. METHODS: Patients diagnosed 
with schizophrenia were included in a retrospective study conducted using the 
Veterans Health Administration (VHA) Medical SAS Datasets. The study period 
was from January 1, 2006 to May 31, 2012. Health care resource utilization and 
costs were assessed in the 12-month follow-up period. Descriptive statistics were 
calculated as means ± standard deviation (SD) and percentages to measure 
treatment, cost, and utilization distribution in the sample. RESULTS: For VHA 
patients diagnosed with schizophrenia (n=59,691), the most common 
comorbidities were counseling not otherwise specified (21.25%), other specified 
counseling (19.42%) and unspecified essential hypertension (18.90%). 52.56% of 
patients were prescribed oral anti-psychotic therapy (OAT) and 2.43% were 
prescribed long-acting anti-psychotic therapy (LAT). The most commonly 
prescribed medications after diagnosis were risperidone (20.66%), simvastatin 
(17.58%), quetiapine (17.21%), omeprazole (15.16%), lisinopril (14.79%) and aspirin 
(13.58%). Percentages of inpatient (38.13%), emergency room (ER) (35.19%), 
physician office (98.86%), and outpatient visits (99.08%) were also calculated. 
Patient expenditures were found to be $18,162 (SD= $65,948) for inpatient, $517 
(SD=$1,333) for ER, $10,366 (SD=$14,243) for physician office and $11,074 
(SD=$14,923) for outpatient visits. CONCLUSIONS: Results suggest that 
risperidone was the most frequently prescribed medication after a diagnosis of 
schizophrenia. However, more research is needed to better understand adverse 
events and side effects of risperidone.  
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OBJECTIVES: To examine the treatment, clinical and economic burden of mental 
disorders in the U.S. veteran population. METHODS: Patients diagnosed with 
mental disorders were studied in a retrospective study (1/1/2006-5/31/2012) using 
the Veterans Health Administration Medical SAS Datasets. The mental disorders 
studied included mood disorder, attention deficit hyperactivity disorder, panic 
disorder, post-traumatic stress disorder, obsessive-compulsive disorder, 
generalized anxiety disorder, personality disorder, depression, anxiety, suicide, 
and intentional injuries. Using the initial mental disorder diagnosis date as the 
index date, patients were required to have at least 1 year of continuous health 
plan benefits pre- and post-index date. Health care resource utilization and costs 
were assessed for the 12-month follow-up period. Descriptive statistics were 
calculated as means ± standard deviation (SD) and percentages to measure 
treatment, cost, and utilization distribution in the sample. RESULTS: Among 
patients identified with mental disorders (n=1,644,214), 48.60% were diagnosed 
with depression, 46.56% with mood disorders, and 21.57% with intentional 
injuries. The most common comorbidities were unspecified essential 
hypertension (21.07%), counseling not otherwise specified (18.35%), and other 
specified counseling (15.92%). 38.88% of patients were prescribed anti-depressant 
treatment, and 15.99% anti-cholinergic treatment. The most commonly 
prescribed medications were simvastatin (20.09%), lisinopril (15.36%), 
omeprazole (14.49%), citalopram hydrobromide (14.26%), and 
hydrochlorothiazide (8.47%). Percentages of inpatient (18.90%), emergency room 
(ER) (27.50%), physician office (99.51%), and outpatient visits (99.77%) were also 
calculated. Patient expenditures were found to be $6,893 (SD= $36,727) for 
inpatient, $312 (SD=$1,085) for ER, $7,249 (SD= $11,523) for physician office and 
$7,820 (SD=$12,262) for outpatient visits. CONCLUSIONS: Depression and mood 
disorders were the most prevalent mental disorders. Anti-depressant drugs were 
the most commonly prescribed medication type during the 60 days after mental 
disorder diagnosis. Mental disorders were associated with high health care 
utilizations, and created a significant cost burden on the health care system.  
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OBJECTIVES: Post-traumatic stress disorder (PTSD) is a type of anxiety disorder that 
occurs after experiencing a traumatic event, and can lead to severe impairment of a 
patient’s daily life. The study aims to assess the clinical and economic burden of 
PTSD in the U.S. veteran population. METHODS: Patients diagnosed with PTSD 
(International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM]: 309.81) were selected from the Veterans Health Administration (VHA) database 
(October 1, 2006-May 31, 2010). The first observed diagnosis date was defined as the 
index date. Continuous medical and pharmacy benefits were required 12-months 
pre- and post-index date. The top ten most common comorbidities were calculated 
for the 12-month baseline period. The top ten treatments were calculated for 60 
days post-index date. Health care resource utilization (inpatient, outpatient, office, 
emergency room [ER] visits), and costs (inpatient, outpatient, ER, pharmacy total 
costs) were assessed for the 12-month follow-up period. Descriptive statistics were 
calculated as means ± standard deviation (SD) and percentages to measure 
treatment, cost, and utilization distribution in the sample. RESULTS: For VHA PTSD 
patients (n=488,770), the most common comorbidities were essential hypertension 
(19.07%) and depressive disorder (13.42%.%). 50.43% of patients were prescribed 
anti-depressant treatment, and 15.35% anti-cholinergics treatment. The most 
commonly prescribed medications were citalopram hydrobromide (17.94%), 
simvastatin (15.47%), omeprazole (12.26%), lisinopril (11.92%), and trazodone 
(11.30%). Percentages of inpatient (16.10%), ER (22.76%), physician office (99.86%), 
and outpatient visits (99.89%) were also calculated. Patient expenditures were found 
to be $5,240 (SD= $29,382) for inpatient, $264 (SD=$822) for ER, $8,437 (SD= $10,803) 
for physician office and $8,926 (SD=$11,443) for outpatient visits. CONCLUSIONS: 
Results suggest that hypertension and depressive disorder are the most common 
comorbidities during the baseline period. Anti-depressant prescriptions were most 
prevalent during the 2-month follow-up period. PTSD was associated with high 
inpatient and ER visit rates, translating into a high cost burden.  
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OBJECTIVES: To determine trends in Attention Deficit Hyperactivity Disorder 
(ADHD) medication use and expenditures in the US from 2000 to 2010. 
METHODS: This was a retrospective cross-sectional analysis of the household 
component of the Medical Expenditure Panel Survey (MEPS) data from 2000 to 
2010 (using the full-year consolidated data files and prescribed medicines files) 
involving all ADHD patients (International Classification of Disease 9th revision 
[ICD-9] code 314) on any FDA approved ADHD medication. Outcome measures 
were ADHD medication utilization and cost (adjusted to 2010 dollars). Since 
